Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
Darmkanker vaker ontdekt in vroeg stadium, minder operaties en betere overleving
mrt 2024 | Maag-darm-leveroncologie